Next-ldha, MCI-1 & P97 to 2 - funding base award ldha RAT & mice mutiple dose admin studies 8/15/16-7/30/18 pre-clin TOX study of drug DEV for cancer patients & other diseases HHSN261201600019I…

Ended Awarded Last action

Contract number
HHSN26100002
Awardee
Awarding agency
Obligated
$0

Award facts

Opportunity
Contract value
$0.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
Pricing
Cost Plus Fixed Fee
Place of performance
Chicago, IL 60612, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00001 · Preclinical toxicology of drugs developed for cancer patients -$44,550
Original award $44,550

Description

Next-ldha, MCI-1 & P97 to 2 - funding base award ldha RAT & mice mutiple dose admin studies 8/15/16-7/30/18 pre-clin TOX study of drug DEV for cancer patients & other diseases HHSN261201600019I DTP-16-062 TPB

Quick answers

Who was awarded contract HHSN26100002?

HHSN26100002 was awarded to University Of Illinois by National Cancer Institute (National Institutes of Health) on September 1, 2016.

How much is contract HHSN26100002 worth?

The government has obligated $0 on HHSN26100002.

Is contract HHSN26100002 an order under another contract?

Yes. HHSN26100002 is a delivery order under HHSN261201600019I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.

Was contract HHSN26100002 competed?

The extent of competition for HHSN26100002 was full and open competition. The government received 4 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award